Antibody-drug conjugates (ADCs) are an emerging form of targeted cancer therapy that have shown promise for HR-positive/HER2-negative metastatic breast cancer.
Like traditional chemotherapy, ADCs are administered intravenously at an infusion center.
ADCs have two key components that make them highly targeted and very potent: 1. Monoclonal antibodies, which attach to the HER-2 protein on cancer cells 2. Cytotoxic drugs (chemotherapy), which kill cancer cells
Because the monoclonal antibodies in ADCs bring chemotherapy directly to the cancer cells, healthy cells are spared from damage.
The side effects of ADCs can be similar to traditional chemotherapy, including nausea, vomiting, and fatigue, but these side effects may be less pronounced, because the drug is so targeted.
ADCs may slow cancer progression and help people with HR-positive/ HER2-negative metastatic breast cancer live longer.
Replay
